Optimal Duration of MRI Follow-up to Safely Identify Middle Ear Residual Cholesteatoma.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
07 2021
Historique:
received: 11 06 2020
accepted: 15 02 2021
pubmed: 17 4 2021
medline: 13 10 2021
entrez: 16 4 2021
Statut: ppublish

Résumé

Previous studies have demonstrated the usefulness of non-EPI DWI for detection of residual cholesteatoma. However, limited data are available to determine the suitable duration of imaging follow-up after a first MR imaging with normal findings has been obtained. The present study aimed to determine the optimal duration of non-EPI DWI follow-up for residual cholesteatoma. A retrospective, monocentric study was performed between 2013 and 2019 and included all participants followed up after canal wall up tympanoplasty with at least 2 non-EPI DWI examinations performed on the same 1.5T MR imaging scanner. MR images were reviewed independently by 2 radiologists. Sensitivity and specificity values were calculated as a function of time after the operation. Receiver operating characteristic curves were analyzed to determine the optimal follow-up duration. We analyzed 47 MRIs from 17 participants. At the end of the individual follow-up period, a residual cholesteatoma had been found in 41.1% of cases. The follow-up duration ranged from 20 to 198 months (mean, 65.9 [SD, 43.9] months). Participants underwent between 2 and 5 non-EPI DWI examinations. Analyses of the receiver operating characteristic curves revealed that the optimal diagnostic value of non-EPI DWI occurred 56 months after the operation when the first MR imaging performed a mean of 17.3 (SD, 6.8) months after the operation had normal findings (sensitivity = 0.71; specificity = 0.7, Youden index = 0.43). Repeat non-EPI DWI is required to detect slow-growing middle ear residual cholesteatomas. We, therefore, recommend performing non-EPI DWI for at least the first 5 years after the initial operation.

Sections du résumé

BACKGROUND AND PURPOSE
Previous studies have demonstrated the usefulness of non-EPI DWI for detection of residual cholesteatoma. However, limited data are available to determine the suitable duration of imaging follow-up after a first MR imaging with normal findings has been obtained. The present study aimed to determine the optimal duration of non-EPI DWI follow-up for residual cholesteatoma.
MATERIALS AND METHODS
A retrospective, monocentric study was performed between 2013 and 2019 and included all participants followed up after canal wall up tympanoplasty with at least 2 non-EPI DWI examinations performed on the same 1.5T MR imaging scanner. MR images were reviewed independently by 2 radiologists. Sensitivity and specificity values were calculated as a function of time after the operation. Receiver operating characteristic curves were analyzed to determine the optimal follow-up duration.
RESULTS
We analyzed 47 MRIs from 17 participants. At the end of the individual follow-up period, a residual cholesteatoma had been found in 41.1% of cases. The follow-up duration ranged from 20 to 198 months (mean, 65.9 [SD, 43.9] months). Participants underwent between 2 and 5 non-EPI DWI examinations. Analyses of the receiver operating characteristic curves revealed that the optimal diagnostic value of non-EPI DWI occurred 56 months after the operation when the first MR imaging performed a mean of 17.3 (SD, 6.8) months after the operation had normal findings (sensitivity = 0.71; specificity = 0.7, Youden index = 0.43).
CONCLUSIONS
Repeat non-EPI DWI is required to detect slow-growing middle ear residual cholesteatomas. We, therefore, recommend performing non-EPI DWI for at least the first 5 years after the initial operation.

Identifiants

pubmed: 33858822
pii: ajnr.A7116
doi: 10.3174/ajnr.A7116
pmc: PMC8324276
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1313-1319

Informations de copyright

© 2021 by American Journal of Neuroradiology.

Références

Int J Pediatr Otorhinolaryngol. 2015 Aug;79(8):1268-74
pubmed: 26071017
Int J Pediatr Otorhinolaryngol. 2019 Mar;118:90-96
pubmed: 30599286
Otol Neurotol. 2017 Apr;38(4):521-528
pubmed: 28195998
J Neuroradiol. 2015 Jul;42(4):193-201
pubmed: 25015879
J Int Adv Otol. 2017 Apr;13(1):1-8
pubmed: 28059056
Clin Otolaryngol. 2011 Aug;36(4):306-12
pubmed: 21564557
Clin Otolaryngol Allied Sci. 1976;1(2):169-82
pubmed: 1031660
Otol Neurotol. 2016 Apr;37(4):356-61
pubmed: 26905824
Otol Neurotol. 2019 Aug;40(7):911-919
pubmed: 31219966
Skull Base. 2008 Sep;18(5):353-9
pubmed: 19240835
Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Jun;131(3):153-8
pubmed: 24709404
Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Jun;129(3):136-40
pubmed: 21955464
AJNR Am J Neuroradiol. 2008 Aug;29(7):1363-8
pubmed: 18417598
Radiology. 2013 Nov;269(2):504-10
pubmed: 23801772
Otol Neurotol. 2019 Jun;40(5):638-644
pubmed: 31083089
Otol Neurotol. 2008 Jun;29(4):513-7
pubmed: 18520587
J Otolaryngol Head Neck Surg. 2019 Nov 7;48(1):58
pubmed: 31699154
J Neuroradiol. 2020 Nov;47(6):433-440
pubmed: 30951771

Auteurs

A-L Fourez (AL)

From the Departments of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.).

M Akkari (M)

From the Departments of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.).

G Gascou (G)

Neuroradiology (G.G., P.-H.L.), University Hospital Gui de Chauliac.

P-H Lefevre (PH)

Neuroradiology (G.G., P.-H.L.), University Hospital Gui de Chauliac.

C Duflos (C)

Department of Medical Information and Biostatistics (C.D.), University Hospital La Colombière, University of Montpellier, Montpellier, France.

A Kaderbay (A)

From the Departments of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.).

M Mondain (M)

From the Departments of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.).

F Venail (F)

From the Departments of ENT and Head and Neck Surgery (A.-L.F., M.A., A.K., M.M., F.V.) f-venail@chu-montpellier.fr.
Institute for Neurosciences de Montpellier (F.V.), Institut National de la Santé et de la Recherche Médicale U1051 and University of Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH